IMA

ImageneBio, Inc. IMA

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,913 of 2,925

Why it scores 7Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$37.33M total
BVF INC/IL
$6.55M0.0%
Blue Owl Capital Holdings LP
$5.41M-4.3%
ORBIMED ADVISORS LLC
$5.36M+140.2%
Cable Car Capital, LP
$4.61M+3.6%
Omega Fund Management, LLC
$2.69M0.0%
RTW INVESTMENTS, LP
$1.97M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$1.89M-1.4%
Trails Edge Capital Partners, LP
$1.66MNew
BML Capital Management, LLC
$1.18M0.0%
Monashee Investment Management LLC
$1.13MNew
BlackRock, Inc.
$797.0K+4.5%
Stonepine Capital Management, LLC
$539.0KNew
RENAISSANCE TECHNOLOGIES LLC
$512.9K+6.4%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$393.3K0.0%
CITADEL ADVISORS LLC
$328.1K-55.3%
GEODE CAPITAL MANAGEMENT, LLC
$315.8K-10.7%
NEA Management Company, LLC
$295.0K0.0%
NANO CAP NEW MILLENNIUM GROWTH FUND L P
$295.0K+66.7%
HSBC HOLDINGS PLC
$208.4K-1.9%
Sofinnova Ventures Inc
$188.1K0.0%
VANGUARD FIDUCIARY TRUST CO
$162.1K+0.7%
Rangeley Capital, LLC
$118.5K-38.4%
TWO SIGMA INVESTMENTS, LP
$117.4KNew
Aldebaran Capital, LLC
$106.9K-2.4%
Shay Capital LLC
$106.7K-5.5%
See all 36 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMA

Earnings Per Share

13fpro.ai/company/IMA

Loading ratio trend…

IMA key financials by period

Reported revenue, net income and operating margin by fiscal year, from ImageneBio, Inc.'s annual filings on SEC EDGAR.

ImageneBio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$800.0K$-45.3M—
FY 2024$3.5M$-36.6M—
FY 2023$9.2M$-68.2M—
FY 2022$15.6M$-68.8M—
FY 2021$31.0M$-34.1M-110.2%
FY 2020$9.2M$-44.3M—
Source: IMA filings on SEC EDGAR →

Companies similar to IMA

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

IMA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About ImageneBio, Inc. (IMA): stock profile, AI score and financials

ImageneBio, Inc. (IMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMA at 6.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,913 of 2,925 stocks — the bottom half of the AI-ranked universe. IMA scores in the top quartile across institutional flow (88.0). Areas of concern include revenue scale (0.3) and revenue growth (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of IMA by reported 13-F value include BVF, Blue Owl Capital, ORBIMED ADVISORS, based on the most recent SEC filings. IMA trades on the Nasdaq exchange and files with the SEC under CIK 1835579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImageneBio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1835579 →